IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 702 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (332 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed118    
    Printed2    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2021  |  Volume : 53  |  Issue : 2  |  Page : 176-177
 

Randomized trial of vilazodone versus sertraline in depression: concerns and comments


Department of Psychiatry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India

Date of Submission04-Mar-2021
Date of Decision26-May-2021
Date of Acceptance26-Apr-2021
Date of Web Publication26-May-2021

Correspondence Address:
Dr. Samir Kumar Praharaj
Department of Psychiatry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal - 576104, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijp.IJP_288_20

Rights and Permissions



How to cite this article:
Praharaj SK. Randomized trial of vilazodone versus sertraline in depression: concerns and comments. Indian J Pharmacol 2021;53:176-7

How to cite this URL:
Praharaj SK. Randomized trial of vilazodone versus sertraline in depression: concerns and comments. Indian J Pharmacol [serial online] 2021 [cited 2021 Jun 13];53:176-7. Available from: https://www.ijp-online.com/text.asp?2021/53/2/176/316945




Sir,

Bathla and Anjum reported results of a randomized trial comparing vilazodone and sertraline in depression.[1] They found both the drugs to be equally effective for depressive symptoms, whereas vilazodone had an advantage in terms of sexual adverse effects and weight gain. However, there are several concerns regarding the conduct of the study.

As mentioned in the study, a total of 71 patients were recruited, of which 11 “did not complete the second follow-up assessment.” It appears that 71 patients were randomized and received treatment; however, only results of 60 completers are presented. The figure representing the flow of participants is confusing. Ideally, all patients randomized into treatment should be included in the analysis, i.e., to conduct an intent-to-treat analysis.

It mentions that the second author of the study performed a randomization procedure, prescribed the treatment to the patients, and carried out all the assessments. Hence, it is unlikely that allocation concealment and blinding were ensured in the study. A small block size of four also makes the allocation predictable.

Inclusion criteria mention including only married patients of 21 years and above; the reason for the same is unclear. This can affect the generalizability of the findings. Furthermore, “patients who were not taking any psychotropic medication for the past 3 months at least” are not “drug naïve,” but refers to “drug-free” patients. There was no mention of the study's primary outcome, and no a priori sample size estimation was done. It is unclear from the description whether the patients received treatment for 3 months or 6 months as part of the study. The actual dosage of medications received by the patients is not mentioned. The Chi-square test should not be done when there are zero values in cells; instead, a Fisher's exact test is more appropriate.

Almost one-third of the patients in the sertraline group had mild depression, which could have affected the results through a possible “floor effect.” Other illness characteristics of the sample such as the age of onset, duration of depressive episode, family history were not reported. Although it was a randomized clinical trial, the protocol was not registered in any trial registry.

It is recommended that CONSORT guideline is followed while conducting and reporting any clinical trial to improve the quality and transparency.[2] Furthermore, all protocols should be registered prospectively in the trial registry and accessible to readers.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Bathla M, Anjum S. A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression. Indian J Pharmacol 2020;52:10-5.  Back to cited text no. 1
  [Full text]  
2.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:e1-37.  Back to cited text no. 2
    




 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow